The pharmaceutical industry is experiencing a shift in innovation focus, especially in weight loss and diabetes treatments, strongly influenced by the COVID-19 pandemic. Historically centered around oncology and immunology, companies are now investing heavily in GLP-1 agonists like Ozempic and Wegovy. These medications have been game-changers for treating not only type 2 diabetes but also for weight management, resulting in significant global sales increases. Patent strategies are crucial, particularly with impending expirations that could open markets to generics, reshaping competitive dynamics.
The rapid evolution of the pharmaceutical industry, particularly in the growing weight loss and diabetes and obesity treatment market, underscores the critical role of innovation and the need for well-developed patent strategies.
Historically, oncology and immunology were the primary targets for pharmaceutical companies, with most resources and capital allocated to developing new technologies in these areas.
The rapid expansion of this pharmaceutical sector is largely driven by treatments using GLP-1 agonists, which have shown considerable increases in global sales.
In Brazil, the primary patent for semaglutide is set to expire in 2026, paving the way for the introduction of generic drugs into the Brazilian market.
Collection
[
|
...
]